Full text
PDF





Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- DENGLER H., REICHEL G. Die Beeinflussung der Blutdruckwirkung von Dopa und Dops durch einen Decarboxylase-Inhibitor. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1957;232(1):324–326. [PubMed] [Google Scholar]
- GILLESPIE L., Jr Clinical pharmacology of newer anthypertensive agents, monoamine oxidase and decarboxylase inhibitors, bretvlium tosvlate, and guanethidine. Ann N Y Acad Sci. 1960 Oct 11;88:1011–1020. doi: 10.1111/j.1749-6632.1960.tb20092.x. [DOI] [PubMed] [Google Scholar]
- GILLESPIE L., Jr, OATES J. A., CROUT J. R., SJOERDSMA A. Clinical and chemical studies with alpha-methyl-dopa in patients with hypertension. Circulation. 1962 Feb;25:281–291. doi: 10.1161/01.cir.25.2.281. [DOI] [PubMed] [Google Scholar]
- OATES J. A., GILLESPIE L., UDENFRIEND S., SJOERDSMA A. Decarboxylase inhibition and blood pressure reduction by alpha-methyl-3,4-dihydroxy-DL-phenylalanine. Science. 1960 Jun 24;131(3417):1890–1891. doi: 10.1126/science.131.3417.1890. [DOI] [PubMed] [Google Scholar]
- ONESTI G., BREST A. N., NOVACK P., MOYER J. H. Pharmacodynamic effects and clinical use of alpha methyldopa in the treatment of essential hypertension. Am J Cardiol. 1962 Jun;9:863–867. doi: 10.1016/0002-9149(62)90211-4. [DOI] [PubMed] [Google Scholar]
- REICHEL G., DENGLER H. Hemmung der Dopadecarboxylase durch alpha-Methyl-dopa in vivo. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1958;234(4):275–281. [PubMed] [Google Scholar]
- SCHAUB F., NAGER F., SCHAER H., ZIEGLER W., LICHTLEN P. [alpha-Methyl-DOPA. Therapeutic experiences in hypertension and biochemical research on its mode of action]. Schweiz Med Wochenschr. 1962 May 19;92:620–628. [PubMed] [Google Scholar]
- SOURKES T. L. Inhibition of dihydroxy-phenylalanine decarboxylase by derivatives of phenylalanine. Arch Biochem Biophys. 1954 Aug;51(2):444–456. doi: 10.1016/0003-9861(54)90500-7. [DOI] [PubMed] [Google Scholar]
- WESTERMANN E., BALZER H., KNELL J. Hemmung der Serotoninbildung durch alpha-Methyl-Dopa. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1958;234(3):194–205. [PubMed] [Google Scholar]